<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01249638</url>
  </required_header>
  <id_info>
    <org_study_id>ML22011</org_study_id>
    <nct_id>NCT01249638</nct_id>
  </id_info>
  <brief_title>Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC</brief_title>
  <official_title>Randomized, Open, Multicenter Phase III Study With Capecitabine Plus Bevacizumab Versus Capecitabine Plus Irinotecan Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient with multiple metastases, not eligible for surgery, might not profit from intensive
      chemotherapy regimens. Therefore less intensive regimens focusing on survival and disease
      control may be a better choice for first line treatment. Therefore this study investigates
      the combination of capecitabine and bevacizumab versus the combination of capecitabine,
      bevacizumab and irinotecan. In case of progressive disease, the therapy in patients treated
      with capecitabine and bevacizumab is intensified by adding irinotecan. Primary endpoint is
      time-of-failure strategy (TFS) comparing both treatment arms.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TFS</measure>
    <time_frame>9 months</time_frame>
    <description>Time of Failure Strategy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR, OS, Quality of Life, PFS-1</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">516</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Cap+Bev until PD followed by CAPIRI +Bev</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitabine + Bevacizumab
In case of Progression Escalation to:
Capecitabine + Irinotecan + Bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capiri + Bev</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine + Irinotecan + Bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine:2 x 1250 mg/m2 day 1-14 followed by 1 week pause q day 21</description>
    <arm_group_label>Cap+Bev until PD followed by CAPIRI +Bev</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab: 7.5 mg/kg day 1 q day 21</description>
    <arm_group_label>Cap+Bev until PD followed by CAPIRI +Bev</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine: 2 x 800mg/m2 day 1-14 followed by 1 week pause q day 21</description>
    <arm_group_label>Capiri + Bev</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan: 200 mg/m2 day 1 , q day 21</description>
    <arm_group_label>Capiri + Bev</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab: 7.5 mg/kg day 1, q day 21</description>
    <arm_group_label>Capiri + Bev</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the colon or rectum.

          -  Stage IV disease.

          -  ECOG 0-1.

          -  Patients considered suitable for application of chemotherapy.

          -  Age 18 - 75 years.

          -  In- or outpatient treatment.

          -  Estimated life expectancy &gt; 3 months.

          -  Measurable index lesion according to RECIST criteria. Evaluation of tumor
             manifestations ≤ 2 weeks prior to treatment start.

          -  Effective contraception.

          -  Adequate hematologic function: leukocytes &gt;= 3000/µl, neutrophils &gt;= 1500/µl,
             platelets &gt;= 100.000/µ, and hemoglobin &gt;= 9g/dl. Bilirubin &lt;= 1,5x upper limit of
             normal (ULN). ALAT and ASAT &lt;= 2,5x ULN, in case of liver metastases &lt;= 5x ULN. Serum
             creatinine &lt;= 1,5x ULN.

          -  No operations within 4 weeks prior to treatment start. No cytologic biopsies within 1
             week prior to treatment start. Operation sequels need to be completely healed. Major
             operations must not be expected at time of study begin, except for potential secondary
             resection of liver metastases. In case of secondary resection of liver metastases,
             bevacizumab must be discontinued 6-8 weeks prior to surgery.

          -  No relevant toxicities due to prior medical treatment at time of study entry.

        Exclusion Criteria:

          -  primary resectable metastases

          -  heart failure Grade III/IV (NYHA-classification)

          -  Prior treatment directed against the epidermal growth factor receptor (EGFR).

          -  Prior treatment with bevacizumab.

          -  Prior chemotherapy for colorectal cancer, except for adjuvant chemotherapy dating back
             &gt; 6 months prior to study entry.

          -  Experimental medical treatment within 30 days prior to study entry.

          -  Known hypersensitivity reaction to any study medication.

          -  Pregnant or breast feeding women (pregnancy needs to be excluded by testing of
             beta-HCG).

          -  Known or suspected cerebral metastases.

          -  Clinically significant coronary heart disease, myocardial infarction within the last
             12 months or high risk of uncontrolled arrhythmia.

          -  Acute or subacute ileus, chronic inflammatory bowel disease or chronic diarrhea.

          -  Abdominal or tracheo-esophageal fistulas, gastrointestinal perforation within 6 months
             before study entry

          -  Symptomatic peritoneal carcinosis.

          -  Severe chronic wounds, ulcera or bone fracture.

          -  Uncontrolled hypertension.

          -  Severe proteinuria (nephrotic syndrome).

          -  Arterial thromboembolic events or hemorrhage within 6 months prior to study entry
             (except tumor bleeding surgically treated by tumor resection).

          -  Bleeding diatheses or coagulopathy.

          -  Full dose anticoagulation.

          -  Known DPD-deficiency (special screening not required).

          -  Known glucuronidation-deficiency (special screening not required).

          -  Contraindication with irinotecan

          -  Medical history of other malignant disease within 5 years prior to study entry, except
             for basalioma, and in-situ cervical carcinoma if treated with curative intent.

          -  Known alcohol or drug abuse.

          -  Medical or psychiatric condition which contradicts participation of study.

          -  Limited legal capacity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volker Heinemann, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Munich - Klinikum der Universitaet Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sebastian Stintzing, Dr. med.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Munich - Klinikum der Universitaet Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clemens Giessen</last_name>
    <role>Study Chair</role>
    <affiliation>University of Munich - Klinikum der Universitaet Muenchen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Volker Heinemann, Prof. Dr.</last_name>
    <phone>+49 89 7095 0</phone>
    <email>volker.heinemann@med.uni-muenchen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Munich - Klinikum der Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Heinemann, Prof. Dr. med.</last_name>
      <phone>+49 89 7095 0</phone>
      <email>volker.heinemann@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Clemens Giesse, Dr. med.</last_name>
      <phone>+49 89 7095 0</phone>
      <email>clemens.giessen@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Volker Heinemann, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clemens Giessen, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2010</study_first_submitted>
  <study_first_submitted_qc>November 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2010</study_first_posted>
  <last_update_submitted>March 11, 2011</last_update_submitted>
  <last_update_submitted_qc>March 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Volker Heinemann, Prof. Dr. med.</name_title>
    <organization>University of Munich - Klinikum der Universitaet Muenchen</organization>
  </responsible_party>
  <keyword>Bevacizumab</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>mCRC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

